Recursion delivered a phenotypic microglia map to Roche/Genentech under a collaboration and received a $30 million milestone payment, the latest tranche in a multi‑hundred‑million dollar partnership. The dataset consists of tens of millions of microglial cell images and perturbation profiles intended to speed target discovery in neurodegenerative diseases. Recursion said the map will be used across neuroscience programs at Roche and Genentech and that the partnership has now generated more than $213 million in payments to Recursion. The deliverable is the second neuroscience map optioned in the collaboration and follows prior phenomap deliveries. The product exemplifies growing commercial interest in large, high‑content cellular atlases as tools for target ID and phenotypic screening in neurology.